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Abstract
Treatment of patients with failed back surgery syndrome (FBSS) with predominant low back pain (LBP) remains challenging.
High-frequency spinal cord stimulation (HF10 SCS) is believed to achieve significant pain reduction. We aimed to evaluate the
real-life efficacy of HF-10 SCS in a tertiary spine center. A prospective observational study of all patients with FBSS and
predominant LBP who underwent HF-10 SCS surgery was performed between 2016 and 2018. Patients > 18 years with
Visual Analogue Scale (VAS) scores of ≥ 5 for LBP and pain duration > 6 months under stable medication were implanted
percutaneous under general anesthesia and a trial phase of 7–14 days was accomplished. Primary end point was a successful trial
defined as ≥ 50% VAS score reduction for LBP. Thirty-four of 39 (85%) subjects had a successful trial. Fifty-three percent were
female and the mean age was 69 years. Median follow-up lasted for 10 months. Devices were removed after a median of
10 months in 5 cases. Remaining 29 patients stated significant VAS score reduction for LBP from 8.1 to 2.9 and VAS for leg
pain from 4.9 to 2.2. Twenty-four percent of all patients were able to discontinue their opioids. Eight of 9 patients (89%) with
signs of adjacent disc disease and 7 of 10 (70%) patients with hardware failure were successfully implanted with significant VAS
reduction for LBP. HF-10 SCS achieves significant pain reduction in most patients with FBSS and predominant LBP. It might be
an efficient alternative to revision surgery.
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Introduction
Failed back surgery syndrome (FBSS) is defined as a persis-
tent or recurrent pain, mainly in the lower back and/or legs,
even after previous anatomically successful spinal surgery
[18]. It is a disabling condition, which affects up to 30% of
patients with previous spine surgery [18]. The prevalence of
FBSS increases with the number of spinal surgeries performed
[17]. FBSS may lead to depression, sleep disturbances, opioid
abuse, and dependence as well as burdening socioeconomic
problems [16]. Conventional tonic paresthesia-based spinal
cord stimulation (SCS) has been applied for decades in pa-
tients who suffered of FBSS with predominant neuropathic
leg pain with significant positive therapeutic effect. In the
last decade, new wave forms like burst stimulation, as well
as new modalities like high-frequency (HF) stimulation,
were developed for patients with chronic refractory low
back pain (LBP) with predominant limb pain [19]. HF-
SCS has previously been applied at low amplitudes, in or-
der to remain sub-threshold for sensory activation and
paresthesia-free [6]. Currently published studies showed
that sub-threshold stimulation at frequencies > 5 kHz can
achieve significant pain relief for LBP compared with low-
er frequencies or sham stimulation [2]. Most of the avail-
able data on paresthesia-free HF-SCS originates from ran-
domized multicenter studies with industrial sponsoring [5].
The aim of this study is to provide independent real-world
data from a tertiary spine center.
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A prospective observational study of all consecutive patients
with FBSS with predominant LBP (VAS ≥ 5) treated between
January 2016 and November 2018 was performed in a single
high-volume spine center. The study was performed accord-
ing to the Declaration of Helsinki and ethical consent was
obtained (registration nr. 409/13).
Inclusion criteria were prior medical history of thoracic or
lumbar surgeries with either decompression alone or instrumen-
tation and decompression, at least 6 months of persistent intrac-
table LBP with or without neuropathic component under con-
servative pain treatment with or without opioids. A psycholog-
ical assessment was performed preoperatively to rule out major
depression, bipolar or psychotic disorder. Exclusion criteria
were age < 18 years, no prior spinal surgeries, a causal correlate
on spinal imaging (e.g., tumor, infection, or major spinal insta-
bility or spinal stenosis related to the patients’ symptoms), and
no prior regular pain medication or extensive conservative treat-
ment. Patients meeting all criteria were enrolled in our prospec-
tive study and first underwent a trial phase with percutaneous
epidural placement of two HF10-SCS leads (10 kHz Senza sys-
tem, Nevro®) in general anesthesia at the Th8-Th10 level
(Fig. 1). Fluoroscopic imaging was performed intraoperatively
and on the first postoperative day as well as on follow-up exam-
ination. The trial phase lasted for 7–14 days and a successful trial
was defined as ≥ 50% pain reduction of VAS scores for LBP.
Patients who benefitted from the trial phase were implanted with
a permanent implantable pulse generator (IPG, Senza I or II
rechargeable IPGs, Nevro®) in general or local anesthesia.
The primary end point of this study was a VAS score reduction
of ≥ 50% for LBP; secondary end points were discontinuation of
opioid medication and rate of surgical complications.
We used SPSS for statistical tests and performed an inde-
pendent samples t test and ANOVA for descriptive analysis
and to exploit the differences between the implanted and
explanted patients. The chi-square test was further applied
for testing significance of parameters.
Results
Demographics
In total, 34 of 39 patients (85%) were initially successfully
implanted with HF10-SCS after a mean time of 21 days
Fig. 1 Left: Schematic display of
electrode placement. Right:
Correct lead placement at Th8–10
level
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[range 7–84] after initial testing (Fig. 2). Fifty-three percent
(n = 18) of the implanted patients were female, and 47%
(n = 16) were male. The mean age was 69 years [range
31–86]. Median age of the implanted patients was 69 years
[range 31–86] while the median age of the explanted pa-
tients cohort was 72 years [range 49–81] (p = 0.669). VAS
scores for back and leg pain preoperatively were equally
distributed in both groups of implanted and explanted pa-
tients (VAS 8.1 back in implanted vs VAS back 7.6 in
explanted patients, p = 0.418; VAS leg 4.9 in implanted vs
VAS leg 7.4 in explanted patients, p = 0.054). The percuta-
neous lead implantation for the successfully implanted pa-
tients had a mean duration of 63 min [range 34–107 min]
and the IPG surgery a mean duration of 32 min [range 11–
94 min]. In patients, who were later explanted due to loss of
treatment response, initial leads implantation lasted a mean
of 103 min [range 67–138 min], which was statistically
significantly longer (p = 0.018). IPG implantation in those
patients lasted in mean 31 min [range 20–37]. Median
follow-up examinations were performed after 10 months
[range 4–24] for all patients.
Trial outcome
In total, 6 patients (15%) experienced a trial failure
(Table 1). Although all patients were psychologically
assessed before being scheduled for surgery, two pa-
tients (5%, patient 1 and 5) suffered from a worsening
of their previously described minor depressive disorder
after being implanted. One patient (3%, patient 2)
lacked even after multiple appointments and phone calls
the essential compliance due to a language barrier and
could not experience a significant treatment effect. One
patient (3%, patient 6) was excluded due to lack of
compliance related to progressive Parkinson’s disease
with cognitive deficits. The remaining two patients
(5%, patients 3 and 4) who experienced a negative trial
phase were not able to achieve a sufficient pain reduc-
tion even after reprogramming the devices with ampli-
tudes up to 1.5 mA (0.5 mA steps) and applying dual
programs with multiple contacts (8 contacts simulta-
neously) or intervals with on/off stimulation.
n=40 eligible patients 
n=34 (85%) permanent 
IPG 
n=5 (15%) patients explanted 
n=29 (85%) patients successfully 
treated with HF10-SCS 
n=6 (15 %) negative trials 
Fig. 2 Study patients distribution






Previous spine surgery Trial
phase
(days)
Comorbidities Main reason for
treatment failure
1 77 f Multiple surgeries with lumbar
stabilization and decompression
for DDD L1-L5
17 Depressive disorder under stable medication,
alcohol abuse, arterial hypertension, prior
hypertensive ICH
Lack of compliance
2 51 m Discectomy and re-discectomy
for disc herniation L4-S1
21 Arterial hypertensive disease, smoking Insufficient pain
reduction
3 89 m Multiple surgeries with stabilization
and decompression for DDD L4-L5
5 Periphery arterial disease, polyneuropathy,
smoking, carotid stenosis, renal
insufficiency
Lack of compliance
4 68 f Decompression for spinal stenosis L3-S1 3 Insufficient pain
reduction
5 40 f Stabilization and discectomy for thoracic
disc herniation Th11-Th12
4 Depressive disorder under stable medication,
smoking
6 79 m Multiple surgeries with stabilization
L2-L4 and decompression for DDD
and spondylolisthesis






The implants were removed after a median of
13 months [range 4–36 months] in four cases due to a
secondary loss of effect on pain and response to treat-
ment and after 4 months in one case due to a persisting
wound healing disorder, which developed over the lead
anchors due to a low-grade bacterial infection with
streptococcus B specimen. Interestingly two of the
explanted patients responded initially excellent to
HF10-SCS therapy and lost significant amount of body
weight because of being able to resume sports activities.
Simultaneously however both of them experienced loss
of therapeutic effect after 1 and 3 years respectively
even after reprogramming the devices. Lead migration
was excluded on X-ray imaging in both cases and an-
algesics and opioid therapy were adapted to patients’
complaints. However, one of those patients continued
to repeatedly complain about pocket pain so revision
surgery of IPG was performed and the IPG, which
was initially placed in the gluteal area, was transposed
in the abdominal fat. As the patient still remained un-
satisfied with the surgical result, the device was re-
moved. The other patient was reprogrammed multiple
times and later on stated no benefit. There was no sig-
nificant correlation between prior instrumentation (p =
0.574), age (p = 0.669), or sex (p = 0.798) and the rate
of explantation in our patient cohort. The remaining 29
patients (74%) had a significant and persistent pain re-
duction for LBP from VAS 8.1 to 2.9 and limb pain
from VAS 4.9 to 2.2 (Fig. 3).
Further analysis of the study cohort investigating the
sagittal imbalance (sagittal vertical axis = SVA > 50 mm)
revealed that SVA was pathologically increased in
explanted patients and marginal in those with negative
trials (median SVA in implanted patients: 37 mm/
median SVA in explanted patients: 69 mm/median
SVA in patients with negative trial: 47 mm). This might
have correlated with a mechanical component of low
back pain on axial load in those patients, which poten-
tially exceeded or intensified the neuropathic pain as
well. However, it is still debatable whether sagittal im-
balance is the cause of low back pain or whether it only
correlated with postoperative mechanical complications.
Furthermore, 19 of 28 (68%) implanted patients, 4 of 5
(80%) explanted patients, and 4 of 6 negative trials
(67%) used to have neuropathic leg pain prior to sur-
gery, which also improved with HF10 SCS therapy
(VAS reduction of leg pain from 7 to 3). There were
only 4 of 28 (14%) implanted patients and 1 of 6 (17%)
with negative trials who were previously treated with
discectomy without spinal fusion. Five of 28 (18%) of
the implanted patients and 1 of 6 (17%) of those with
negative trials suffered from low back pain without neu-
ropathic component, though there was no significant
difference for all subgroups considering the lumbar
and leg pain outcome with SCS therapy (Table 2).
Pain medication
Twenty-five percent (10/40) of the initially recruited pa-
tients did not take prior opioid medication before initi-
ation of the HF10-SCS treatment and they neither re-
quired any opioids postoperatively. Twenty-four percent
(7/29) of the permanently implanted patients were able
to completely and permanently discontinue their opioid
medication on follow-up examination, relying on
NSAID analgesics occasionally. The majority of patients
were on gabapentin or pregabalin medication in combi-
nation with SCS therapy (13 of 28 successfully im-
planted patients, 3 of 5 explanted, and 1 of 6 negative
trials) due to neuropathic pain. This type of medication



















Fig. 3 HF10-SCS therapeutic
effect based on VAS scores
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Device-related problems
We monitored patients immediately postoperatively and on
follow-up examinations throughX-ray imaging in order to detect
any hardware failure. Twenty-four percent (7/29) of all perma-
nently implanted patients experienced a lead migration on X-ray
imaging during follow-up examinations (Table 3, Fig. 4). There
was no significant loss of treatment effect due to lead migration
in these cases and no patient required a revision surgery. Two
patients (5%) were diagnosed with postoperative infections—
one located in the anchoring area and the second one over the
IPG. In the first case, we detected a low-grade bacterial infection
with Streptococcus B specimen. The second patient was preop-
eratively already at high-risk with poorly controlled diabetes and
complained ten days postoperatively after the IPG implantation
of sweating, fever, and purulent discharge of the wound. No
bacterial species could be identified in microbiological analysis.
Both patients were explanted and treated with intravenous anti-
biotics for 2 weeks (ampicillin/sulbactam and doxycycline). The
latter patient demanded a reimplantation and experienced suffi-
cient pain relieve at follow-up, and the first patient preferred no
further surgical treatment. Anchor pain occurred in a single pa-
tient (3%) and was managed initially through higher gabapentin
dosage and on long-term through a revision surgery in local
anesthesia with multiple sutures of the anchors in the muscle
fascia, showing a significant symptom relief. Only one of the
permanently implanted patients complained about pocket pain
and was advised to a revision surgery in local anesthesia with
transposition of the IPG above the iliac crest (Fig. 5).
Adjacent segment disease and hardware failure
Twenty-four patients (62%) had received dorsal or dorsoven-
tral lumbar or thoracolumbar instrumentations and the remain-
ing 15 patients (38%) were treated with discectomies or de-
compression surgeries prior to SCS therapy (Figs. 6 and 7).
Twenty-six patients (6%) of our cohort would normally oth-
erwise have been advised to revision spine surgery—7 pa-
tients (18%) for decompression alone and 19 patients (49%)
for further extension of the preexisting instrumentation due to
adjacent disc disease (ADD) or hardware failure with screw
loosening, cage sintering, and/or rod breakage (Table 4,
Figs. 8 and 9). In our study, 9 patients (23%) initially present-
ed with persistent LBP (on average VAS score of 9) and
radiological signs of ADD in the proximal spinal level without
Fig. 4 Lead migration on follow-up









LBP w/o neuropathic pain 9 3 0 0
Discectomy alone 8,5 2,5 2,5 1,5
Neuropathic leg pain 9 3 7 3
SVA >50 9 3 0 1
Gabapentin /pregabalin usage 9 3 7 3
Table 3 Device revision characteristics
Implanted Explanted Total
Infection 1 1 2
Lead migration 4 1 5
Pocket pain 1 1 2
Anchor pain 1 0 1
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major spinal canal stenosis (Table 5). Eight of 9 (89%) pa-
tients were permanently implanted and stated a significant
improvement on follow-up examinations with a mean VAS
score reduction from 8.6 to 2.6 for LBP and a mean VAS
reduction from 4.5 to 2.3 for leg pain (Table 6). Patients di-
agnosed with hardware failure were identified with
heterogenic imaging findings like screw loosening (7 patients,
18%), rod breakage (1 patient, 3%), and non-union with cage
sintering (2 patients, 5%). Seven of 10 (70%) patients with
hardware failure were successfully implanted and stated a sig-
nificant improvement of VAS scores for LBP from 8.3 to 3
and VAS score reduction for leg pain from 7.6 to 2.3 (Tables 5
and 6; Figs. 6 and 7).
Discussion
A sustainable and effective pain reduction was achieved
in all implanted patients for back and leg pain over a
mean follow-up period of 10 months. Constant pain
reduction of 64% for LBP in 85% of all patients was
observed. This real-world data is similar to the pub-
lished results from previous randomized controlled trials
[3, 10]. To date, neuromodulation is indicated in neuro-
pathic LBP without a clear mechanical pain that may be
attributed to the patient’s symptoms [11]. In our patient
cohort, neuropathic pain was not considered a mandato-
ry inclusion criterion for test trial enrolment. In contrast
to multiple revision surgeries with re-discectomies or
extensive instrumentations, which might also have been
suitable for some of our patients, we maintained a high
back pain improvement with very low complication
rates (2.5% infection rate, no postoperative hematoma
or broken leads on follow-up, no significant therapy
loss despite lead migration) and short surgical times.
In a recent meta-analysis of 37 studies with 1483 pa-
tients, Dower et al. showed that although greater im-
provement of back pain was achieved in patients under-
going re-discectomy and fusion compared to re-
discectomy alone, the rate of a satisfactory outcome
was similar in both groups [8]. Indeed patients who
undergo stabilization surgeries are exposed to higher
risks for reoperation than patients who receive decom-
pression alone [9]. With increasing numbers of fusion
and decompression surgeries in the last two decades, the
number of FBSS patients without radiological correlate
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Fig. 5 Device-related complications
Table 4 Hardware failure data
Implanted Explanted Negative trial
Screw loosening 5 1 1
Rod breakage 0 1 0
Cage sintering 2 0 0
Neurosurg Rev
necessarily associated with improved pain scores, but
have a higher rate of complications including increased
bleeding, infections, acute respiratory distress syndrome,
longer hospital stays, and higher mortality rates than the
primary surgeries [7]. According to the randomized con-
trolled trial (RCT) by North et al. comparing SCS to
further surgical interventions (decompression alone or
decompression with fusion), the mean costs per success-
ful outcome for revision surgery were on average
$57,571 higher than a successful randomization to SCS
therapy, which emphasizes the cost-efficiency of SCS
implantation [15]. In addition, North et al. also demon-
strated in a level I RCT that conventional SCS therapy
is more effective than repeated surgery for a subpopu-
lation of FBSS patients [14]. However, North et al. did
not apply HF10-SCS therapy on their patient cohort,
which is supposed to be even more effective on the
long-term for FBSS patients with LBP. Kapural et al.
demonstrated in the SENZA trial (level I RCT) a higher
effectiveness of HF10-SCS compared to tonic low-
frequency SCS providing higher responder rates for leg
(83%) and back (85%) pain [10]. A recent review about
treatment options for FBSS patients by Amirdelfan et al.
indicates that there is currently no level I evidence for
success of revision spine surgery in those patients.
Moreover, the only two existing level II studies showed
no significant differences in pain and disability scores
or Oswestry Disability Index (ODI) between a surgical
intervention and conservative options [4]. According to
our results, HF-10 SCS appears to be a viable option
for patients with mechanical low back pain.
Interestingly we experienced significantly longer sur-
gical times (103 min vs 70 min) for percutaneous epi-
dural lead placement in patients who were later
explanted. Even though X-ray imaging in those cases
confirmed correct lead placement intra- and postopera-
tively, an extensive scar tissue in the spinal canal due to
prior surgeries might have led to lead placement diffi-
culties and later therapy loss.
Treatment of patients with concomitant degenerative
spine disease and Parkinson’s disease remains very chal-
lenging. In our series, two patients with Parkinson’s
disease were ultimately non-responders to HF-10 thera-
py. One patient had a negative test trial (patient 6) and
the second patient experienced loss of initial treatment
effect following 3 months after IPG implantation. In
recent literature, there are only a few case reports and
case series dealing with SCS treatment in patients with
Parkinson’s disease. However, Parkinson’s should not
be an exclusion criterion as several patients reportedly
improved in walking posture, rigidity, and pain intensity
through spinal cord stimulation [8, 9].
In our study, a high number of patients (24%) were
able to discontinue their opioids on follow-up. Those
are similar results to larger studies like the SENZA trial,
in which over one-third of all subjects who received
HF10-SCS therapy were able to reduce or wean off
their opioids despite an average of 13 years of prior
chronic pain [13].
We did not encounter any severe mechanical compli-
cations, e.g., lead fracture or disconnection, which has a
reported incidence between 5 and 9%. We did not ob-
serve clinically evident treatment loss due to lead mi-
gration even though on follow-up imaging we detected
a moderate lead migration in 24% of all permanently
implanted patients. Lead migration has a reported inci-
dence in the literature between 0 and 27% [19]. These
hardware complications can be minimized by using ap-
propriate leads, anchoring, and suturing techniques.
Kapural et al. demonstrated in SENZA-RCT that signif-
icant lead migration requiring intervention in both the
HF10-SCS and the traditional SCS arms occurred in
only less than 5% of all cases [10].













Implanted 6 18 10 8 7 4 13
Explanted 3 3 2 0 2 1 3
Negative trial 0 3 3 1 1 2 3
Total 9 24 15 9 10 7 19
Percent 23% 62% 38% 23% 26% 18% 49%
Table 6 HF-10 efficacy in ADD and hardware failure
ADD Hardware failure
Back pain baseline 8.6 ± 0.9 8.3 ± 1
Leg pain baseline 4.5 ± 4.8 7.6 ± 1.6
Back pain with HF-10 2.6 ± 1.5 3 ± 1.2
Leg pain with HF-10 2.3 ± 1.5 2.3 ± 1.3
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Several studies have demonstrated the benefit of nov-
el SCS therapies over traditional low-frequency SCS for
the treatment of patients with chronic low back and/or
leg pain. SENZA-RCT showed that paresthesia-free
HF10-SCS was superior to low-frequency stimulation
for treatment of chronic low back pain with leg pain.
The SUNBURST crossover trial recently found that
high-frequency burst stimulation was preferred over
low-frequency tonic SCS with patients citing better pain
relief and a preference for paresthesia-free SCS [12].
However, it is impossible to state whether some patients
experienced pain relief due to placebo effect since high-
frequency neuromodulation works paresthesia-free. HF10-
SCS blocks large-diameter fibers from producing action
potentials, which mostly carry information of vibration
and pressure, and hence would avoid inducing paresthesia.
The same stimulation activates medium- and smaller-
diameter dorsal column fibers, which leads to spinal pain
inhibition through gate control mechanisms [1]. However,
no published study has inferred potential neurophysiologi-
cal or neurochemical changes that may occur subtly and
slowly but progressively after paresthesia-free HF-SCS as
for activation of wide dynamic range (WDR) neurons or
suppression of Aβ-fibers (supra-threshold) and synaptic
transmission of C-fibers [6].
Conclusion
HF10-SCS therapy is able to achieve highly satisfactory
pain reduction in most patients with FBSS with predom-
inant mechanical LBP. In summary, HF10-SCS therapy
may contribute to an efficient, cost-effective, and less
invasive alternative to revision spine surgery in patients






















Revision Surgery Data 
Implanted Explanted Negative Trial Total 









Back Pain Baseline Leg Pain Baseline Back Pain with 
HF-10 
Leg Pain with 
HF-10 
HF-10 Cases considered for Revision Spine Surgery 
ADD Hardware failure 
Fig. 6 HF-10 cases considered
for revision spine surgery
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Fig. 8 Exemplary case for
adjacent disc disease—multiple
revision for osteoporotic fractures
with adjacent segment disease
and no major stenosis
Fig. 9 Exemplary case for
hardware failure—screw loosen-
ing of S1 pedicle screws and
pseudarthrosis L5/S1 after multi-
ple revision surgeries for infec-
tious lumbar CSF fistula and ini-
tial instrumentation for DDD
Neurosurg Rev
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